Importantly, such mutated MRE11 gene has been shown to sensitize CRC cells to agents causing DNA replication inhibition [165], as well as PARP-1 inhibition [101,103], suggesting that targeting MRE11 in MSS CRC might be an interesting therapeutic strategy. The gene discussed is PARP1; the disease is colorectal carcinoma.